IL17A and rheumatoid arthritis: Based on the above, therapeutic substances that particularly impede the production of TNF-α, IL-1β, IL-6 and IL-17 distinguish a crucial target for RA treatment (Jing et al., 2019; Rui et al., 2019; Yu et al., 2019).